Private Company Edition: Westlake Village BioPartners’ latest launch 3T Biosciences also licensed a second TCR platform from Stanford University. In other recent financings, Senda raised a $123m series C round, Orna revealed a $221m series B and CPRIT funded several cancer drug developers.

$47.5m partnership between the foundation and Broad researchers will mine genetic data for insights into disease mechanisms. MD Anderson, Nuvectis each unveil multiple new tie-ups.

The center is partnering with Obsidian to make autologous TILs work better after being infused back into patients by using IL-15, which may be less toxic than the high-dose IL-2 currently used.

In tandem with buying the rest of Kleo, Tonix licenses molecular degradation technology from Yale. Neurogene, University of Dundee partner on cell therapies for neurological disorders.